Cannabis: pharmacology and toxicology in animals and humans
IB Adams, BR Martin - Addiction, 1996 - Wiley Online Library
Cannabis is one of the most widely used drugs throughout the world. The psychoactive
constituent of cannabis, δ 9 ‐tetrahydrocannabinol (δ 9 ‐THC), produces a myriad of …
constituent of cannabis, δ 9 ‐tetrahydrocannabinol (δ 9 ‐THC), produces a myriad of …
Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor …
IB Adams, DR Compton, BR Martin - Journal of Pharmacology and …, 1998 - ASPET
Anandamide is the newly discovered endogenous cannabinoid ligand that binds to brain
cannabinoid receptors and shares most, but not all, of the pharmacological properties of Δ 9 -…
cannabinoid receptors and shares most, but not all, of the pharmacological properties of Δ 9 -…
Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs.
IB Adams, W Ryan, M Singer, BF Thomas… - … of Pharmacology and …, 1995 - ASPET
Recent evidence implicates anandamide as the endogenous ligand for the cannabinoid
receptor. One purpose of this study was to determine the structural requirements for …
receptor. One purpose of this study was to determine the structural requirements for …
Structure− activity analysis of anandamide analogs: relationship to a cannabinoid pharmacophore
BF Thomas, IB Adams, SW Mascarella… - Journal of medicinal …, 1996 - ACS Publications
Anandamides are endogenous fatty acid ethanolamides that have been shown to bind to
the cannabinoid receptor and possess cannabimimetic activity yet are structurally dissimilar …
the cannabinoid receptor and possess cannabimimetic activity yet are structurally dissimilar …
Pharmacological and behavioral evaluation of alkylated anandamide analogs
IB Adams, W Ryan, M Singer, RK Razdan… - Life sciences, 1995 - Elsevier
Anandamide (arachidonylethanolamide), isolated from porcine brain, has been shown to
bind to the cannabinoid receptor and also to produce cannabimimetic activity in …
bind to the cannabinoid receptor and also to produce cannabimimetic activity in …
Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).
S Adams, JR Diamond, EP Hamilton, PR Pohlmann… - 2016 - ascopubs.org
1009 Background: Atezolizumab (atezo; MPDL3280A) is a humanized MAb that inhibits
binding of PD-L1 to PD-1 and B7.1, thus restoring tumor-specific T-cell immunity. Atezo has …
binding of PD-L1 to PD-1 and B7.1, thus restoring tumor-specific T-cell immunity. Atezo has …
An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer
Purpose: Endoglin, an endothelial cell membrane receptor expressed on angiogenic tumor
vessels, is essential for angiogenesis and upregulated in the setting of VEGF inhibition. …
vessels, is essential for angiogenesis and upregulated in the setting of VEGF inhibition. …
[PDF][PDF] The Civil War Letters of James Rush Holmes
IB Adams - Western Pennsylvania History: 1918-2022, 1961 - journals.psu.edu
… of Marcellin C Adams, a great-nephew of Rush Holmes. "Janev >" Miss Sarah Jane Adams,
… Adams, long-time valued member of this Society, the Daughters of the American Revolution …
… Adams, long-time valued member of this Society, the Daughters of the American Revolution …
Glycoprotein Ib‐mediated platelet activation: A signalling pathway triggered by thrombin
F Adam, MC Guillin… - European Journal of …, 2003 - Wiley Online Library
Platelet activation by thrombin plays a major role in the development of haemostasis and
thrombosis. Thrombin activates human platelets by cleaving the N‐terminal region of G‐protein…
thrombosis. Thrombin activates human platelets by cleaving the N‐terminal region of G‐protein…
Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain …
S Hurvitz, R Singh, B Adams… - … in medical oncology, 2018 - journals.sagepub.com
Background: Improving outcomes for patients with human epidermal growth factor 2-positive
(HER2+) central nervous system (CNS) metastases remains an unmet clinical need. This …
(HER2+) central nervous system (CNS) metastases remains an unmet clinical need. This …